Date: 2012-04-05
Type of information: Development agreement
Compound: monoclonal antibodies generated with Chiome’s proprietary ADLib® system
Company: GSK (UK) Chiome Bioscience (Japan)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: cancer,autoimmune diseases
Details: GSK and Tokyo-based biotechventure company, Chiome Bioscience, have entered into a pilot study and option agreement. Under the agreement, Chiome and GSK will generate monoclonal antibodies with Chiome’s proprietary ADLib® system for GSK’s research and evaluation use with an option for development.
The ADLib® system is an innovative technology for antibody generation by leveraging gene conversion of chicken DT40 cells. It generates antibodies quite fast, potentially in about 10 days entirely in vitro. Also it generates antibodies with, theoretically, unlimited diversification, which allows for the development of antibodies that have been considered to be difficult by currently available methods. Chiome has already succeeded in generating highly specific monoclonal antibodies against four transmembrane proteins using a novel antibody screening method based on animal cells expressing targeted antibodies.
The two partners believe that the combination of GSK R&D activities with Chiome’s technology for antibody generation has the potential to accelerate drug discovery and advance pharmaceutical development which offers new treatment options to patients suffering from cancer and autoimmune diseases.
Financial terms:
Latest news:
